Moreover, in recent years, it has been documented that mutations targeting the binding sites of splicing factors on pre-mRNA can disrupt the proper function of the spliceosome, leading to aberrant alternative splicing of genes associated with cancer [54,55]. This evidence concerns the gene SLU7 and cancer.